How would you approach adjuvant therapy for a post-menopausal women with cT2 cN0 TNBC on biopsy s/p neoadjuvant chemotherapy and mastectomy who is later found to have RCB2 HR+ breast cancer on surgical pathology?
HR+ = ER 34%, PR 0%
RCB2 = no nodal involvement
Answer from: Medical Oncologist at Academic Institution
First, is she BRCA positive? If so, there is a role for olaparib in adjuvant setting (OlympiA trial). I would treat with capecitabine as per the CREATE X trial (Masuda et al., PMID 28564564). Although the subset of triple negative cancers benefited most, and the point estimate for the ER or PR posit...
Sign in or Register to read more